The Role of Exercise Training in the Treatment of Resistant Hypertension (EnRIcH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03090529 |
|
Recruitment Status :
Completed
First Posted : March 24, 2017
Last Update Posted : December 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Resistant Hypertension | Other: Exercise Group | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Role of Exercise Training in the Treatment of Resistant Hypertension |
| Actual Study Start Date : | March 30, 2017 |
| Actual Primary Completion Date : | December 30, 2019 |
| Actual Study Completion Date : | March 30, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Exercise group
The 12-week exercise-training program will include three sessions of aerobic exercise per week
|
Other: Exercise Group
The 12-week exercise-training program will include three sessions of aerobic exercise per week |
|
No Intervention: Control group
The control group will receive usual medical care
|
- Ambulatory blood pressure [ Time Frame: Change from Baseline in Blood Pressure at 3 months ]Blood pressure
- Casual blood pressure [ Time Frame: Change from baseline to 3 months ]Blood pressure
- Body composition [ Time Frame: Change from baseline to 3 months ]Body composition
- Health-related quality of life [ Time Frame: Change from baseline to 3 months ]Health-related quality of life will be evaluated by the Short-Form 36.
- Arterial stiffness [ Time Frame: Change from baseline to 3 months ]Carotid-femoral pulse wave velocity, central pressures and aortic augmentation index and augmentation pressure.
- Heart rate variability [ Time Frame: Change from baseline to 3 months ]Recordings of R-R interval data; The R-R interval will be analyzed using time domain, frequency domain and Poincare´ plot techniques.
- Circulating number of endothelial progenitor cells, circulating endothelial cells, nitric oxide and endothelial Nitric Oxide Synthase [ Time Frame: Change from baseline to 3 months ]These markers will inform endothelial function, damage and repair
- Inflammation [ Time Frame: Change from baseline to 3 months ]Plasma levels of inflammatory and anti-inflammatory biomarkers.
- Oxidative stress [ Time Frame: Change from baseline to 3 months ]Plasma levels of oxidative stress and antioxidant markers.
- Daily physical activity [ Time Frame: Change from baseline to 3 months ]Physical activity will be measured during 7 consecutive days using an accelerometer.
- Dietary intake [ Time Frame: Change from baseline to 3 months ]Dietary intake will be assessed using a 4-day food diary.
- VO2 max [ Time Frame: Change from baseline to 3 months ]VO2 max will be determined by the Chester step test.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: confirmed resistant hypertension, who in the previous 3 months had unchanged medication
Exclusion Criteria:
- Patients with secondary hypertension
- Evidence of target organ damage
- Patients with heart failure
- Previous cardiovascular event
- Peripheral artery disease
- Renal failure
- Chronic obstructive pulmonary disease
- Systolic office blood pressure superior to 180 mmHg
- Biomechanical limitations to physical activity
- Those participating in regular physical activity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03090529
| Portugal | |
| Cardiology Department, Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga | |
| Aveiro, Portugal, 3800 | |
| Hypertension and Cardiovascular Unit, Hospital Pedro Hispano, ULS Matosinhos | |
| Matosinhos, Portugal, 4464-513 | |
| Study Director: | José Mesquita Bastos, MD, PhD | Hospital Infante D. Pedro, Centro Hospitalar Do Baixo Vouga |
| Responsible Party: | Fernando Ribeiro, Adjunct Professor, Aveiro University |
| ClinicalTrials.gov Identifier: | NCT03090529 |
| Other Study ID Numbers: |
1725/2014 |
| First Posted: | March 24, 2017 Key Record Dates |
| Last Update Posted: | December 17, 2020 |
| Last Verified: | December 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Exercise training Ambulatory blood pressure Resistant Hypertension Nitric Oxide |
|
Hypertension Vascular Diseases Cardiovascular Diseases |

